All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Federation Bio Inc., which just closed a $50 million series A, had enough preclinical data in engineering bacteria to drive the immune system up or down that it actually could have become two separate companies, its new CEO told BioWorld.